US Patent

US8952018 — Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors

Method of Use · Assigned to GlaxoSmithKline LLC · Expires 2030-10-15 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a combination of the MEK inhibitor trametinib dimethyl sulfoxide and the B-Raf inhibitor dabrafenib, and methods of using this combination.

USPTO Abstract

A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2020 — trametinib-dimethyl-sulfoxide
U-2020 — trametinib-dimethyl-sulfoxide
U-2027 — dabrafenib-mesylate
U-2020 — trametinib-dimethyl-sulfoxide
U-2027 — dabrafenib-mesylate

Patent Metadata

Patent number
US8952018
Jurisdiction
US
Classification
Method of Use
Expires
2030-10-15
Drug substance claim
No
Drug product claim
No
Assignee
GlaxoSmithKline LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.